Table 2 Duration of treatment with first-line ibrutinib
Ibrutinib n = 136 | |
|---|---|
Median (range) duration of ibrutinib treatment, monthsa | 57.1 (0.7–66.0) |
Treatment duration, n (%) | |
>3 years | 99 (73) |
>4 years | 88 (65) |
>5 years | 37 (27) |
Continuing ibrutinib on study, n (%) | 79 (58) |
Continuing on commercial ibrutinib, n (%) | 0 (0) |
Discontinued ibrutinib, n (%) | 56 (41) |
Adverse event | 29 (21) |
Progressive disease | 8 (6) |
Death | 8 (6) |
Withdrawal by patient | 7 (5) |
Investigator decision | 4 (3) |
